Sex differences in response to tadalafil in pulmonary arterial hypertension

Chest

Volumn 147, Issue 1, 2015, Pages 188-197

  Mathai, Stephen C ^a   Hassoun, Paul M ^a   Puhan, Milo A ^b   Zhou, Yi ^c   Wise, Robert A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNITED THERAPEUTICS CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TADALAFIL; ANTIHYPERTENSIVE AGENT; CARBOLINE DERIVATIVE; VASODILATOR AGENT;

6 MINUTE WALK DISTANCE; 6 MINUTE WALK TEST; ADULT; AGE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; FUNCTIONAL STATUS ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; SHORT FORM 36; TREATMENT DURATION; TREATMENT OUTCOME; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; EXERCISE TEST; EXERCISE TOLERANCE; FOLLOW UP; HYPERTENSION, PULMONARY; LUNG WEDGE PRESSURE; MARYLAND; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; SEX RATIO;

ANTIHYPERTENSIVE AGENTS; CARBOLINES; DOUBLE-BLIND METHOD; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; MALE; MARYLAND; MIDDLE AGED; PREVALENCE; PULMONARY WEDGE PRESSURE; QUALITY OF LIFE; SEX DISTRIBUTION; SEX FACTORS; TADALAFIL; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84920735760     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-0263     Document Type: Article

References (47)

1. McLaughlin VV, Archer SL, Badesch DB, et al; American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009; 53 (17): 1573-1619.
2. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension n. N Engl J Med. 2002; 346 (12): 896-903.
3. O'Callaghan DS, Dorfmuller P, Jaïs X, et al. Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases? Presse Med. 2011; 40 (1 pt 2): e65 - e78.
4. Barst RJ, Rubin LJ, Long WA, et al; Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996; 334 (5): 296-301.
5. Galiè N, Brundage BH, Ghofrani HA, et al; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009; 119 (22): 2894-2903.
6. Galiè N, Olschewski H, Oudiz RJ, et al; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008; 117 (23): 3010-3019.
7. Galiè N, Ghofrani HA, Torbicki A, et al; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005; 353 (20): 2148-2157.
8. Simonneau G, Barst RJ, Galie N, et al; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebocontrolled trial. Am J Respir Crit Care Med. 2002; 165 (6): 800-804.
9. Chen H, Rosenzweig EB, Gotzkowsky SK, Arneson C, Nelsen AC, Bourge RC. Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension. Health Qual Life Outcomes. 2013; 11 : 31.
10. Pepke-Zaba J, Beardsworth A, Chan M, Angalakuditi M. Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension. Curr Med Res Opin. 2009; 25 (10): 2479-2485.
11. Pepke-Zaba J, Gilbert C, Collings L, Brown MC. Sildenafil improves healthrelated quality of life in patients with pulmonary arterial hypertension. Chest. 2008; 133 (1): 183-189.
12. Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013; 127 (10): 1128-1138.
13. Ghofrani HA, Galiè N, Grimminger F, et al; PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013; 369 (4): 330-340.
14. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010; 55 (18): 1915-1922.
15. McLaughlin V. Managing pulmonary arterial hypertension and optimizing treatment options: prognosis of pulmonary artery hypertension. Am J Cardiol. 2013; 111 (8 Suppl): 10C - 15C.
16. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA. 1999; 282 (8): 790-795.
17. Gabler NB, French B, Strom BL, et al. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest. 2012; 141 (1): 20-26.
18. Mathai SC, Puhan MA, Lam D, Wise RA. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hyper tension. Am J Respir Crit Care Med. 2012; 186 (5): 428-433.
19. Beaton DE, Boers M, Wells GA. Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol. 2002; 14 (2): 109-114.
20. McCabe C, Bennett M, Doughty N, MacKenzie Ross R, Sharples L, Pepke-Zaba J. Patient-reported outcomes assessed by the CAMPHOR questionnaire predict clinical deterioration in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Chest. 2013; 144 (2): 522-530.
21. Suber T, Shao K, Bueso M, et al. Impact of health related quality of life on outcomes in pulmonary arterial hypertension differs by disease type. Am J Respir Crit Care Med. 2013; 187 : A5376.
22. Brooks D, Solway S, Gibbons WJ. ATS statement on six-minute walk test. Am J Respir Crit Care Med. 2003; 167 (9): 1287.
23. Ware JE, Kosinski MA, Dewey JE. How to Score Version 2 of the SF-36 Health Survey. Lincoln, RI : Quality Metric, Inc; 2000.
24. Royston P, Moons KG, Altman DG, Vergouwe Y. Prognosis and prognostic research: developing a prognostic model. BMJ. 2009; 338 : b604.
25. Sauerbrei W. The use of resampling methods to simplify regression models in medical statistics. Appl Stat. 1999; 48(3): 313-329.
26. Shapiro S, Traiger GL, Turner M, McGoon MD, Wason P, Barst RJ. Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and longterm pulmonary arterial hypertension disease management. Chest. 2012; 141(2): 363-373.
27. Miyauchi T, Yanagisawa M, Iida K, et al. Age- and sex-related variation of plasma endothelin-1 concentration in normal and hypertensive subjects. Am Heart J. 1992; 123 (4 pt 1): 1092-1093.
28. Polderman KH, Stehouwer CD, van Kamp GJ, Dekker GA, Verheugt FW, Gooren LJ. Influence of sex hormones on plasma endothelin levels. Ann Intern Med. 1993; 118 (6): 429-432.
29. Stauffer BL, Westby CM, Greiner JJ, Van Guilder GP, Desouza CA. Sex differences in endothelin-1-mediated vasoconstrictor tone in middle-aged and older adults. Am J Physiol Regul Integr Comp Physiol. 2010; 298 (2): R261 - R265.
30. Klinger JR, Abman SH, Gladwin MT. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013; 188 (6): 639-646.
31. Chan MV, Bubb KJ, Noyce A, et al. Distinct endothelial pathways underlie sexual dimorphism in vascular autoregulation. Br J Pharmacol. 2012; 167 (4): 805-817.
32. Forte P, Kneale BJ, Milne E, et al. Evidence for difference in nitric oxide biosynthesis between healthy women and men. Hypertension. 1998; 32 (4): 730-734.
33. Giuliano F, Peña BM, Mishra A, Smith MD. Efficacy results and quality-of-life measures in men receiving sildenafil citrate for the treatment of erectile dysfunction. Qual Life Res. 2001; 10 (4): 359-369.
34. Taichman DB, Shin J, Hud L, et al. Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res. 2005; 6 : 92.
35. Ventetuolo CE, Praestgaard A, Palevsky HI, Klinger JR, Halpern SD, Kawut SM. Sex and haemodynamics in pulmonary arterial hypertension. Eur Respir J. 2014; 43 (2): 523-530.
36. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002; 40 (4): 780-788.
37. Provencher S, Sitbon O, Humbert M, Cabrol S, Jaïs X, Simonneau G. Longterm outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006; 27 (5): 589-595.
38. Gabler NB, French B, Strom BL, et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation. 2012; 126 (3): 349-356.
39. Fritz JS, Blair C, Oudiz RJ, et al. Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension. Chest. 2013; 143 (2): 315-323.
40. Mathai SC. Solvitur ambulando⋯or maybe not? Chest. 2013; 143 (2): 285-287.
41. Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J. 2007; 29 (3): 469-475.
42. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-THE-2. E ur Respir J. 2004; 24 (3): 353-359.
43. Mathai SC, Hassoun PM. Pulmonary arterial hypertension associated with systemic sclerosis. Expert Rev Respir Med. 2011; 5 (2): 267-279.
44. Denton CP, Avouac J, Behrens F, et al. Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. Arthritis Res Ther. 2011; 13 (3): 114.
45. Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. Eur Respir J. 1999; 14 (2): 270-274.
46. Gibbons WJ, Fruchter N, Sloan S, Levy RD. Reference values for a multiple repetition 6-minute walk test in healthy adults older than 20 years. J Cardiopulm Rehabil. 2001; 21 (2): 87-93.
47. Chetta A, Zanini A, Pisi G, et al. Reference values for the 6-min walk test in healthy subjects 20-50 years old. Respir Med. 2006; 100 (9): 1573-1578.